Results 41 to 50 of about 69,132 (251)
JHEP ReportsBackground & Aim: Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) attenuates cytotoxic T lymphocyte (CTL) activation. This study was performed to examine the relationships between CTLA-4 genotypes/haplotypes, hepatitis B surface antigen (HBsAg),
Jia-Feng Wu +7 more
doaj +1 more source
A bispecific protein capable of engaging CTLA-4 and MHCII protects non-obese diabetic mice from autoimmune diabetes. [PDF]
PLoS ONE, 2013 Crosslinking ligand-engaged cytotoxic T lymphocyte antigen-4 (CTLA-4) to the T cell receptor (TCR) with a bispecific fusion protein (BsB) comprised of a mutant mouse CD80 and lymphocyte activation antigen-3 (LAG-3) has been shown to attenuate TCR ...
Hongmei Zhao +10 more
doaj +1 more source
Advanced Science, EarlyView.In the recondite pulmonary neoplastic milieu, DESMIN+ cancer‐associated fibroblasts function as the paramount stromal source of IL‐8, precipitating a deleterious immunological metamorphosis by engaging CXCR2 receptors on the myeloid lineage. This paracrine stimulus triggers a mechanotransduction cascade characterized by RhoA‐dependent actin ...
Xuyu Gu +7 more
wiley +1 more source
Frontiers in ImmunologyAlveolar echinococcosis (AE) is a zoonotic parasitic disease caused by the infection of Echinococcus multilocularis (E. multilocularis) larvae. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) produces inhibitory signals and induces T cell exhaustion, thereby ...
Yuxuan Yang +8 more
doaj +1 more source
A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect
Molecular Therapy: Nucleic Acids, 2017 The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic ...
Bo-Tsang Huang +6 more
doaj +1 more source
Immunity, 2023 Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous success treating B cell malignancies; however, some patients fail to respond due to poor autologous T cell fitness. To improve response rates, we investigated whether disruption of the co-inhibitory receptors CTLA4 or PD-1 could restore CART function.
Sangya Agarwal +19 more
openaire +2 more sources
Advanced Science, EarlyView.A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang +19 more
wiley +1 more source
Advanced Science, EarlyView.A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee +6 more
wiley +1 more source
CTLA-4 expression on antigen-specific cells but not IL-10 secretion is required for oral tolerance
European Journal of Immunology, 2002 CD4(+) T cells play a vital role in mediating the tolerance induced at mucosal sites following exposure to non-pathogenic stimuli, and further understanding of the precise mechanisms by which these cells prevent aberrant responses is required. We have developed a model using transfer of DO11.10 TCR-transgenic bone marrow into irradiated recipients in ...
Fowler, S, Powrie, F
openaire +3 more sources
Advanced Science, EarlyView.Oral WT1‐targeted Bifidobacterium longum vaccine promotes WT1‐associated cellular immunity and enhances anti‐PD‐1/anti‐CTLA‐4 efficacy in pancreatic cancer. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immune checkpoint inhibitors (ICI) due to its profoundly immunosuppressive tumor microenvironment.
Taiki Yamazaki +7 more
wiley +1 more source